Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this interventional clinical trial is compare between two different dose regimens of bisoprolol (beta-blocker) in CABG patients in terms of efficacy and safety.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Bisoprolol

Criteria

Inclusion Criteria:

• Adult patients: 18 to 65 years old

• Diagnosed with coronary heart disease or myocardial infarction and scheduled for coronary artery bypass surgery

Exclusion Criteria:

• History of Ventricular arrhythmia, atrial fibrillation, atrial flutter, left bundle block, AV block grade II/III

• History of Sick sinus syndrome, sinoatrial heart block

• History of valve replacement

• Permanent Pacemaker

• LVEF less than 30%

• Unstable Heart failure

• Cardiogenic shock

• Sustained systolic blood pressure less than 100 mmHg or HR less than 50 bpm at recruitment

• Severe chronic obstructive airway disease

• Severe asthma unless was on previously tolerated bisoprolol dose

• Uncontrolled diabetes mellitus unless was on previously tolerated bisoprolol dose

• Pregnant/Lactation

• Previous recent stroke

• Creatinine clearance less than 30 ml/min

• End stage liver disease (liver cirrhosis)

• Drug dependance history

• Untreated phaeochromocytoma

• Vasospastic angina

• Thyrotoxicosis

• History of advanced staged of peripheral vascular disease

• Hypersensitivity

• Patients on any other beta-blocker other than bisoprolol

• Patients on bisoprolol higher than 5 mg/day.